Summit Therapeutics Inc.

NasdaqGM:SMMT Stock Report

Market Cap: US$2.4b

Summit Therapeutics Balance Sheet Health

Financial Health criteria checks 5/6

Summit Therapeutics has a total shareholder equity of $77.7M and total debt of $100.0M, which brings its debt-to-equity ratio to 128.7%. Its total assets and total liabilities are $202.9M and $125.3M respectively.

Key information

128.7%

Debt to equity ratio

US$100.00m

Debt

Interest coverage ration/a
CashUS$186.24m
EquityUS$77.69m
Total liabilitiesUS$125.26m
Total assetsUS$202.95m

Recent financial health updates

Recent updates

Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress

Jan 30

We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Dec 29
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Summit Therapeutics slips on plans to terminate study for lead candidate

Oct 04

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Aug 17

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Aug 11

Summit to explore additional trial for its bacteria-induced colon infection drug

Jul 14

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Apr 29
Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Dec 23

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator

Jun 22

Summit Therapeutics to join Russell 3000 Index

Jun 08

Financial Position Analysis

Short Term Liabilities: SMMT's short term assets ($189.7M) exceed its short term liabilities ($20.4M).

Long Term Liabilities: SMMT's short term assets ($189.7M) exceed its long term liabilities ($104.9M).


Debt to Equity History and Analysis

Debt Level: SMMT has more cash than its total debt.

Reducing Debt: SMMT had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SMMT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SMMT has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 39.4% each year.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.